These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26165417)

  • 1. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
    Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
    Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    Deek MP; Benenati B; Kim S; Chen T; Ahmed I; Zou W; Aisner J; Jabbour SK
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):147-154. PubMed ID: 26700708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
    Kim YH; Ahn SJ; Kim YC; Kim KS; Oh IJ; Ban HJ; Chung WK; Nam TK; Yoon MS; Jeong JU; Song JY
    Jpn J Clin Oncol; 2016 Feb; 46(2):144-51. PubMed ID: 26590014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
    Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X
    Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
    Wang J; Pang QS; Wang P; Wang J; Wang W
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
    Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
    Dang J; Li G; Zang S; Zhang S; Yao L
    Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
    Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
    Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
    Tabchi S; Blais N; Campeau MP; Tehfe M
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):381-387. PubMed ID: 28083648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.
    Harris JP; Murphy JD; Hanlon AL; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):872-84. PubMed ID: 24495591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.